Evidence map›Paper›PMID 35220840›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Replacing the phthalimide core in thalidomide with benzotriazole.

Mikhail Krasavin, Andrey Bubyrev, Alexander Kazantsev, Christopher Heim, Samuel Maiwald, Daniil Zhukovsky, Dmitry Dar'in, Marcus D Hartmann, Alexander Bunev

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Evolving CRBN ligands enhance the drug-like properties of protein degraders.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
  3. Review
  4. Beilstein journal of organic chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Mikhail KrasavinInstitute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.ORCID 0000-0002-0200-4772
Andrey BubyrevInstitute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Alexander KazantsevInstitute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Christopher HeimDepartment of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, Germany.
Samuel MaiwaldDepartment of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, Germany.
Daniil ZhukovskyInstitute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Dmitry Dar'inInstitute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Marcus D HartmannDepartment of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, Germany.ORCID 0000-0001-6937-5677
Alexander BunevMedicinal Chemistry Center, Togliatti State University, Togliatti, Russia.
St Petersburg University · RUMax Planck Institute for Developmental Biology · DETogliatti State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of proteolysis-targeting chimaeras (PROTACs) mandates that new ligands for the recruitment of E3 ligases are discovered. The traditional immunomodulatory drugs (IMiDs) such as thalidomide and its analogues (all based on the phthalimide glutarimide core) bind to Cereblon, the substrate receptor of the CRL4A

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorEnzyme InhibitorsHumansMolecular StructureStructure-Activity RelationshipTriazolesUbiquitin-Protein LigasesAntineoplastic AgentsbenzotriazoleEnzyme InhibitorsTriazolesUbiquitin-Protein Ligasesbenzotriazolecarbene N-H insertionCereblondiazo compoundsimmunomodulatory drugsphthalimide

Identifiers

PMID35220840
PMCPMC8890552
OpenAlexW4214774992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.